Cryptocurrency Analysis and News Portal
Pascal Soriot, the Chief Executive of AstraZeneca revealed that the vaccine is as effective as Pfizer and can be a strong protector against the new variant of the virus which is very contagious.AstraZeneca Plc (NASDAQ: AZN) has responded to the circulating news concerning the near approval of its COVID-19 vaccine
Read More
Currently, AstraZeneca vaccine trials are in the late-stages, involving about 23,000 participants. The participants span across the UK, U.S., South Africa, and Brazil.British-Swedish pharmaceutical company AstraZeneca Plc (LON: AZN) hopes to release its vaccine data by the end of the year. The drugmaker announced the development as it reports a
Read More
It is unclear whether the volunteer took the vaccine dose or was in a placebo group. AstraZeneca has not provided much information but said they followed all required review processes.hasSoon after resuming the COVID-19 vaccine trial at almost all sites, AstraZeneca plc (NASDAQ: AZN) has faced another challenge. On Wednesday,
Read More
AstraZeneca’s clinical trials for the vaccine were halted in July after one of the participants complained of neurological disorder.Foremost COVID-19 vaccine pharmaceutical firm AstraZeneca Plc (LON: AZN) has disclosed that it has resumed its mid-late stage COVID-19 Vaccine trial in Japan, following the earlier global suspension of the process. As
Read More
AstraZeneca has received partial immunity from the EU in a vaccine deal. The EU has already paid €336 million at €2.5 per dose.AstraZeneca Plc (LON: AZN) has received partial immunity from the European government over its potential vaccine deal. Compared to French pharmaceutical company Sanofi SA (NASDAQ: SNY), AstraZeneca’s vaccine
Read More
In partnership with U.K.’s Oxford University, AstraZeneca said that it will resume the phase three clinical trial for its COVID-19 vaccine contender AZD1222 since it got an approval from UK’s Medicines Health Regulatory Authority. After pausing its work on the coronavirus vaccine citing safety concerns last week, pharmaceutical giant AstraZeneca plc
Read More
With the company’s ongoing late-stage clinical trials and its impressive H1 performance results, AstraZeneca (AZN) stock jumped in the pre-market.Foremost leader in the search for COVID-19 vaccine AstraZeneca Plc (NYSE: AZN) has posted its H1 performance report. The company’s released result shows an impressive earning spiked by increasing demand for
Read More
Data from AstraZeneca’s clinical trials of its COVID-19 vaccine candidate AZD1222 shows promising results but AZN share price has refused to be positively impacted.The world is still ecstatic with the hope of getting a vaccine that can guarantee a lasting and viable solution to the COVID-19 pandemic. As several pharmaceutical
Read More